CAUTION: Varian's Cardiac Radioablation Solution is an Investigational device. Limited by United States law to investigational use.
Not available for sale in any market and no guarantee of future commercialization or feature availability.
About Ventricular Tachycardia
Ventricular tachycardia (VT) is a fast, abnormal heart rate that may lead to sudden cardiac arrest if not treated successfully. VT treatments include use of implantable cardioverter-defibrillators (ICDs), antiarrhythmic medications, and catheter ablation. Catheter ablation involves the delivery of energy through a catheter that is inserted into the femoral artery or vein and guided to the area of the heart where the arrhythmia is occurring. The delivery of the energy causes tissue scarring, which can interrupt the electrical signals causing the irregular heartbeat. Current treatments are often insufficient in controlling VT and can be associated with significant side effects.1,2,3,4 Cardiac radioablation has recently emerged as a non-invasive treatment alternative to catheter ablation for this patient population.
About Varian
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 11,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Back to HCB News
